MarketCap
Facebook
X
Telegram
NanoViricides Net Income | NNVC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income NanoViricides
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.47 M | -8.29 M | -8.59 M | -8.11 M | -8.82 M | -13.4 M | -8.42 M | -8.56 M | -10.3 M | -10.7 M | -2.2 M | -14.1 M | -8.88 M | -6.21 M | -6.48 M | -4.74 M | -2.79 M | -2.74 M | -3.12 M | -3.28 M | -66 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -66 K | -14.1 M | -7.11 M |
Quarterly Net Income NanoViricides
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.13 M | -3.13 M | -3.13 M | -2.36 M | -1.97 M | -1.97 M | -2.22 M | -2.03 M | -3.13 M | - | -1.85 M | -2.11 M | -1.97 M | - | -1.7 M | -1.75 M | -1.57 M | -3.32 M | -1.79 M | -1.92 M | -2.61 M | -4.53 M | -2.11 M | -2.33 M | -2.33 M | -2.33 M | -2.31 M | -1.93 M | -1.93 M | -1.93 M | -1.56 M | -2.23 M | -2.23 M | -2.23 M | -1.84 M | -2.8 M | -2.01 M | -2.8 M | -2.01 M | -1.55 M | -3.06 M | -1.55 M | -3.06 M | -2.78 M | -1.31 M | -2.78 M | -1.31 M | -1.88 M | 852 K | -1.88 M | 852 K | -1.36 M | -6.56 M | -1.69 M | -6.27 M | -1.21 M | -1.8 M | -1.21 M | -1.8 M | -1.39 M | -1.14 M | -1.39 M | -1.14 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 852 K | -6.56 M | -2.16 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
-525 M | - | - | - |  Russia |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
1 M | - | - | $ 621 M |  Britain |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-44.2 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Revolution Medicines
RVMD
|
-1.13 B | $ 207.32 | 0.24 % | $ 39.4 B |  USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-197 K | $ 101.8 | 0.08 % | $ 6.62 B | USA |
|
Rezolute
RZLT
|
-74.4 M | $ 4.4 | 0.88 % | $ 334 M | USA |
 |
Sana Biotechnology
SANA
|
-244 M | $ 3.45 | 0.77 % | $ 874 M | USA |
 |
Seer
SEER
|
-73.6 M | $ 1.95 | 0.26 % | $ 108 M | USA |
 |
Precigen
PGEN
|
-251 M | $ 6.87 | 0.14 % | $ 2.15 B | USA |
 |
SIGA Technologies
SIGA
|
23.3 M | $ 3.2 | 1.86 % | $ 229 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-285 M | $ 19.94 | 0.05 % | $ 1.73 B | USA |
 |
Soligenix
SNGX
|
-11.1 M | $ 0.38 | 1.18 % | $ 1.97 M | USA |
 |
Spruce Biosciences
SPRB
|
-39 M | $ 59.09 | 2.0 % | $ 45.3 M | USA |
 |
Sarepta Therapeutics
SRPT
|
-713 M | $ 20.94 | 0.04 % | $ 2.1 B | USA |
 |
Stoke Therapeutics
STOK
|
-6.88 M | $ 30.05 | 0.81 % | $ 1.78 B | USA |
 |
Sutro Biopharma
STRO
|
-191 M | $ 19.1 | 0.34 % | $ 162 M | USA |
 |
Shattuck Labs
STTK
|
-48.8 M | $ 6.5 | 0.29 % | $ 452 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
-38.6 M | $ 42.43 | 0.23 % | $ 2.4 B | USA |
 |
Savara
SVRA
|
-119 M | $ 5.53 | 2.98 % | $ 1.23 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-6.21 M | $ 2.24 | 0.45 % | $ 1.52 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
108 B | $ 18.32 | 1.49 % | $ 28.9 B |  Japan |
 |
Bio-Techne Corporation
TECH
|
182 M | $ 72.31 | 0.01 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
-52.6 M | $ 1.98 | 2.06 % | $ 77.7 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.41 B | $ 36.76 | 1.21 % | $ 42.1 B | Israel |
 |
TG Therapeutics
TGTX
|
447 M | $ 55.74 | 0.58 % | $ 8.04 B | USA |
 |
Trevi Therapeutics
TRVI
|
-42.8 M | $ 16.82 | 1.17 % | $ 2.27 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-109 M | $ 5.48 | 0.54 % | $ 1.75 B | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-6.13 M | $ 69.37 | 0.35 % | $ 193 M | Israel |
 |
UroGen Pharma Ltd.
URGN
|
-153 M | $ 43.82 | 0.02 % | $ 2.11 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
1.33 B | $ 497.97 | 2.12 % | $ 22.1 B | USA |
 |
Spero Therapeutics
SPRO
|
8.57 M | $ 1.19 | 0.41 % | $ 66.7 M | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
-378 M | $ 57.42 | 3.78 % | $ 6.59 B | USA |
 |
Jounce Therapeutics
JNCE
|
-50.9 M | - | - | $ 98.4 M | USA |
 |
NextCure
NXTC
|
-55.8 M | $ 8.42 | 7.67 % | $ 23.9 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-17.9 M | $ 5.26 | 0.75 % | $ 56 M | USA |
 |
Viridian Therapeutics
VRDN
|
-343 M | $ 23.17 | 1.09 % | $ 2.36 B | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-29.9 M | - | 7.23 % | $ 2.72 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
3.95 B | $ 528.9 | 0.22 % | $ 135 B | USA |
 |
Verastem
VSTM
|
-209 M | $ 8.08 | 0.55 % | $ 560 M | USA |
 |
vTv Therapeutics
VTVT
|
-27 M | $ 32.79 | 0.03 % | $ 130 M | USA |
 |
Voyager Therapeutics
VYGR
|
-120 M | $ 3.4 | 3.85 % | $ 200 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-204 M | $ 4.91 | 1.03 % | $ 828 M | Singapore |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-124 M | $ 13.16 | 0.15 % | $ 112 M | USA |
 |
Xenetic Biosciences
XBIO
|
-2.68 M | $ 4.28 | 0.86 % | $ 7.28 M | USA |
|
XBiotech
XBIT
|
-45.5 M | $ 2.18 | 0.23 % | $ 66.5 M | USA |
 |
Exicure
XCUR
|
-4.95 M | $ 1.41 | 12.8 % | $ 8.88 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-346 M | $ 59.55 | 0.18 % | $ 4.72 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
554 K | $ 8.48 | 0.12 % | $ 1.36 B | USA |